Calcium Acetate

Warnings & Precautions

Calcium acetate should be used cautiously in dogs and cats with chronic kidney disease due to the risk of hypercalcemia and soft tissue mineralization. Appropriate laboratory monitoring is essential during therapy.

• Pre-existing hypercalcemia:
  Contraindicated in patients with hypercalcemia.
• Risk of hypercalcemia:
  Oral calcium products may increase serum calcium concentrations; monitor ionized calcium and phosphorus regularly.
• Calcium × phosphorus product:
  Use cautiously in patients with a serum calcium × phosphorus product greater than 60 due to increased risk of soft tissue mineralization.
• Dependence on food intake:
  Because calcium acetate decreases systemic absorption of dietary phosphorus, patients that are not eating will not benefit from therapy.
• Concurrent calcitriol use:
  Combination with calcitriol is controversial; if used together, intensified monitoring for hypercalcemia is required.
• Laboratory considerations:
  Hemolyzed samples or hyperlipidemia may falsely elevate total calcium results. Hyperbilirubinemia may falsely lower total calcium. Oxalate, citrate, and EDTA anticoagulants can bind calcium and cause falsely low values. Ionized calcium measurement is preferred when available.

Drug Interactions

Calcium acetate may reduce the absorption or alter the effectiveness of several orally administered medications. When concurrent therapy is required, dose separation and monitoring may be necessary.

• Aspirin:
  Concurrent use may decrease salicylate effectiveness.
• Atenolol:
  May reduce atenolol efficacy when administered together.
• Oral bisphosphonates (e.g., alendronate):
  Concurrent oral administration may reduce bisphosphonate absorption; separate doses by at least 2 hours if possible.
• Calcium channel blockers (e.g., amlodipine, diltiazem, verapamil):
  May reduce therapeutic effects of calcium channel blockers.
• Cefpodoxime:
  Concurrent use may decrease cefpodoxime efficacy.
• Ceftriaxone:
  May result in formation of ceftriaxone-calcium precipitates; use caution.
• Digoxin:
  Hypercalcemia may increase risk of serious arrhythmias; concurrent use is not recommended.
• Fluoroquinolones (e.g., enrofloxacin, marbofloxacin):
  Oral calcium-containing products can reduce absorption; separate doses by at least 2 hours.
• Iron:
  May reduce iron absorption and effectiveness.
• Ketoconazole:
  May decrease ketoconazole exposure.
• Levothyroxine:
  May reduce absorption if given simultaneously; separate doses by at least 2 hours.
• Penicillamine:
  Oral calcium-containing products can reduce absorption.
• Oral phosphates:
  Concurrent use may decrease phosphate absorption.
• Sucralfate:
  May reduce sucralfate efficacy.
• Tetracyclines (e.g., doxycycline, minocycline):
  Oral calcium-containing products can reduce absorption; separate doses by at least 2 hours.
• Thiazide diuretics (e.g., hydrochlorothiazide):
  May increase risk of hypercalcemia.
• Trientine:
  Oral calcium-containing products can reduce trientine absorption.
• Vitamin D analogues (e.g., calcitriol, cholecalciferol, ergocalciferol):
  Concurrent use may increase risk of hypercalcemia.

Side Effects & Overdose

Side Effects

The primary concern with calcium acetate therapy in dogs and cats is the development of hypercalcemia, particularly with high doses or long-term use. Careful monitoring is required during treatment.

• Hypercalcemia: Most significant adverse effect; may predispose to extraosseous (soft tissue) calcification.
• Soft tissue mineralization: Risk increases when the calcium × phosphorus product is elevated.
• Gastrointestinal intolerance: Nausea has been reported; decreased appetite or vomiting may occur.

Overdose

Acute overdose may result in clinically significant hypercalcemia. Severity depends on the amount ingested and duration of exposure.

• Hypercalcemia: Monitor for increased thirst and urination, vomiting, decreased appetite, lethargy, or weakness.
• Management: Monitor serum ionized calcium and phosphorus. Provide supportive care as indicated.
• Recent massive ingestion: Consider standard gastrointestinal decontamination protocols if appropriate.
• Consultation: In suspected overdose cases, consultation with a veterinary poison control center is recommended.

Key Notes

Practical clinical considerations for effective use of calcium acetate in dogs and cats with chronic kidney disease:

• Most efficient calcium-based binder:
  Binds approximately 50% more phosphorus than calcium carbonate while delivering a lower elemental calcium load.
• Elemental calcium content:
  Each gram of calcium acetate provides approximately 254 mg of elemental calcium.
• Ionized calcium preferred:
  Directly measured ionized calcium is a more accurate indicator of calcium status than total calcium when monitoring therapy.
• Initial monitoring frequency:
  Recheck serum phosphorus and ionized calcium every 4–6 weeks initially; some clinicians monitor every 10–14 days in higher-risk patients. Once stable, reassess approximately every 3 months.
• Absorption interaction principle:
  As a calcium-containing product, it may reduce absorption of many orally administered drugs; dose separation is often required.
• Storage:
  Store tablets, capsules, and gelcaps at room temperature (approximately 25°C; excursions 15–30°C permitted).